PriceTargets.com logo

IN8bio - INAB Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $10.75
  • Forecasted Upside: 914.15%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$1.06 As of 04/24/2024 01:00 AM ET
▲ +0.02 (1.92%)

This chart shows the closing price for INAB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New IN8bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for INAB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for INAB

Analyst Price Target is $10.75
▲ +914.15% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for IN8bio in the last 3 months. The average price target is $10.75, with a high forecast of $14.00 and a low forecast of $7.50. The average price target represents a 914.15% upside from the last price of $1.06.

This chart shows the closing price for INAB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in IN8bio. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/10/2024HC WainwrightReiterated RatingBuy ➝ Buy$14.00Low
3/18/2024LaidlawInitiated CoverageBuy$7.50Low
3/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$14.00Low
11/13/2023HC WainwrightReiterated RatingBuy ➝ Buy$14.00Low
8/11/2023HC WainwrightReiterated RatingBuy ➝ Buy$14.00Low
4/17/2023EF Hutton Acquisition Co. IReiterated RatingBuy$8.00Low
3/31/2023HC WainwrightReiterated RatingBuy$14.00N/A
3/29/2023EF Hutton Acquisition Co. IInitiated CoverageBuy$8.00Low
11/11/2022B. RileyDowngradeBuy ➝ Neutral$9.00 ➝ $3.00Low
8/30/2022HC WainwrightInitiated CoverageBuy$14.00Low
1/24/2022B. RileyLower TargetBuy$19.00 ➝ $9.00High
9/12/2021MizuhoReiterated RatingBuy$12.00High
8/24/2021MizuhoInitiated CoverageBuy$12.00Medium
8/23/2021B. RileyInitiated CoverageBuy$19.00High
(Data available from 4/25/2019 forward)

News Sentiment Rating

0.06 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2023
  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/28/2023
  • 4 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
11/27/2023
  • 2 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
12/27/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/26/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/25/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2024
  • 0 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024

Current Sentiment

  • 0 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
IN8bio logo
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM. It also develops INB-300, INB-410, and INB-500 that are in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Read More

Today's Range

Now: $1.06
Low: $1.01
High: $1.07

50 Day Range

MA: $1.13
Low: $0.95
High: $1.30

52 Week Range

Now: $1.06
Low: $0.65
High: $3.48

Volume

151,765 shs

Average Volume

314,937 shs

Market Capitalization

$33.91 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of IN8bio?

The following equities research analysts have issued reports on IN8bio in the last twelve months: HC Wainwright, and Laidlaw.
View the latest analyst ratings for INAB.

What is the current price target for IN8bio?

2 Wall Street analysts have set twelve-month price targets for IN8bio in the last year. Their average twelve-month price target is $10.75, suggesting a possible upside of 914.2%. HC Wainwright has the highest price target set, predicting INAB will reach $14.00 in the next twelve months. Laidlaw has the lowest price target set, forecasting a price of $7.50 for IN8bio in the next year.
View the latest price targets for INAB.

What is the current consensus analyst rating for IN8bio?

IN8bio currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe INAB will outperform the market and that investors should add to their positions of IN8bio.
View the latest ratings for INAB.

What other companies compete with IN8bio?

Other companies that are similar to IN8bio include Protara Therapeutics, Cortexyme, Cyclo Therapeutics, Achilles Therapeutics and Orphazyme A/S. Learn More about companies similar to IN8bio.

How do I contact IN8bio's investor relations team?

IN8bio's physical mailing address is 79 Madison Avenue, New York, New York 10016. The company's listed phone number is 646-600-6438 and its investor relations email address is [email protected]. The official website for IN8bio is www.in8bio.com. Learn More about contacing IN8bio investor relations.